NCT02269189已完成1 期
A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses (15-day Dosing) of BIIL 284 BS in Adult (300 mg) and Pediatric (150 mg) Cystic Fibrosis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Changes from baseline in physical examination
研究概览
简要总结
Safety, tolerability and pharmacokinetics following repeated doses (15-day dosing)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 6 years (pediatric 6 - 17 years inclusive; adult ≥ 18 years); minimum weight requirement of 20 kg
- •Confirmed diagnosis of CF (positive sweat chloride ≥ 60 milliequivalents (mEq)/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype
- •Forced expiratory volume in one second (FEV1) > 25% predicted (using prediction equation's of Knudson et al)
- •Clinically stable with no evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within 2 weeks of screening
- •Females of child bearing potential must have a negative pregnancy test at screening and, if sexually active, must be willing to use a double-barrier form of contraception for the duration of the study
- •The patient or the patient's legally acceptable representative must be able to give informed consent in accordance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and local legislation
- •The patient must be able to swallow the BIIL 284 tablet whole
- •Patients taking a chronic medication must be willing to continue this therapy for the entire duration of the study
排除标准
- •Patients with a history of allergy/hypersensitivity (including medication allergy) which is deemed relevant to the trial as judged by the Investigator
- •Patients who have participated in another study with an investigational drug (including BI Trial 543.36) within one month or 6 half-lives (whichever is greater) preceding the screening visit
- •Patients with known substance abuse, including alcohol or drug abuse, within 30 days prior to screening
- •Female patients who are pregnant or lactating
- •Patients who are unable to comply with breakfast requirements prior to dosing
- •Patients who have received IV, oral or inhaled antibiotics or corticosteroids for a pulmonary exacerbation within 2 weeks of screening
- •Patients who have started a new chronic medication for CF within 2 weeks of screening
- •Patients with documented persistent colonization with B. cepacia (defined as more than one positive culture within the past year)
- •Patients with clinically significant findings on chest x-ray which in the opinion of the Investigator precludes the patient's participation in the trial
- •Patients with oxyhemoglobin saturation in room air < 90% by pulse oximetry
- •Patients with hemoglobin < 9.0 g/dL; platelets < 100x10**9/L; prothrombin time (PT) > 1.5 times the upper limit of normal, serum glutamic-oxaloacetic transaminase (ALT) or serum glutamic-pyruvic transaminase (AST) > 2 times the upper limit of normal; creatinine > 1.8 mg/dL (adults) or > 1.4 mg/dL (pediatrics) at screening
- •Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This includes significant hematological, hepatic, renal, cardiovascular, and neurologic disease. Patients with diabetes may participate if their disease is under good control prior to screening.
研究组 & 干预措施
BIIL 284 BS, high dose in adult patients
Experimental
干预措施: BIIL 284 BS, high dose (Drug)
BIIL 284 BS, low dose in pediatric patients
Experimental
干预措施: BIIL 284 BS, low dose (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Changes from baseline in physical examination
时间窗: Pre-dose and 72 hours after last drug administration
Number of patients with clinically relevant findings in vital signs
时间窗: Up to 72 hours after last drug administration
blood pressure, pulse rate, respiratory rate, body temperature
Number of patients with clinically relevant changes in spirometry
时间窗: Pre-dose, up to 72 hours after last drug administration
Number of patients with clinically relevant changes in oximetry
时间窗: Pre-dose, up to 72 hours after last drug administration
Number of patients with clinically relevant changes in 12-lead ECG
时间窗: Pre-dose, up to 72 hours after last drug administration
Number of patients with clinically relevant findings in laboratory evaluation
时间窗: Up to 72 hours after last drug administration
Number of patients with adverse events
时间窗: Up to 72 hours after last drug administration
次要结局
- Terminal half-life of the analyte in plasma (t1/2)(Up to 72 hours after last drug administration)
- Area under the concentration-time curve of the analyte in plasma (AUC)(Up to 72 hours after last drug administration)
- Concentration of the analyte in plasma after 24 hours (C24h)(24 hours after drug administration)
- Terminal rate constant of the analyte in plasma (λz)(Up to 72 hours after last drug administration)
- Maximum measured concentration of the analyte in plasma (Cmax)(Up to 72 hours after last drug administration)
- Time from dosing to the maximum concentration of the analyte in plasma (tmax)(Up to 72 hours after last drug administration)
- Mean residence time of the analyte in the body at steady state (MRTss)(Up to 72 hours after last drug administration)
- Apparent volume of distribution during the terminal phase λz following extravascular administration at steady state (Vz,ss/F)(Up to 72 hours after last drug administration)
- Accumulation ratio for AUC after the 15th dose over the dosing interval compared to the first dose (RA,AUC)(day 1, day 15)
- Pre-dose concentration of the analyte in plasma immediately before administration of the next dose (Cpre)(Up to day 16)
- Accumulation ratio for Cmax after the 15th dose over the dosing interval compared to the first dose (RA,Cmax)(day 1, day 15)
研究者
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) PatientsCystic FibrosisNCT02265679Boehringer Ingelheim45
已完成
1 期
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy MalesNon-alcoholic SteatohepatitisNCT06308861J2H Biotech100
已完成
1 期
A Multiple Dose Study of DWP10292 and UDCA in Healthy Male SubjectsHealthyNCT02622685Daewoong Pharmaceutical Co. LTD.58
已完成
1 期
A Single Dose Study of DWP10292 in Healthy Male SubjectsHealthyNCT01423526Daewoong Pharmaceutical Co. LTD.52
已完成
1 期
Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519DyslipidemiaNCT02156544Chong Kun Dang Pharmaceutical41